AstraZeneca Gets A Reprieve But Will Have To Earn Its Independence
This article was originally published in The Pink Sheet Daily
Pfizer has walked away from AstraZeneca – for now – but the big pharma can make another offer later this year under U.K. takeover laws. AstraZeneca will need to give investors a reason to believe it deserves to go it alone.
You may also be interested in...
The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.